PCNY is excited to offer the Galleri™ Multi-Cancer Early Detection (MCED) Test. One in two men and one in three women will be diagnosed with cancer in their lifetime, and one in five people will die from cancer. Over 70% of cancer deaths are caused by cancers not commonly screened for, with current surveillance screening for approximately one in four cancers (Breast- mammogram/ultrasound; Colorectal- colonoscopy; Prostate- PSA testing; Lung (in high-risk people)- low-dose CT scan; Cervical- PAP smear). Finding cancer early is important to improve treatment outcomes and survival. The great majority of cancers show no symptoms until later stages, when definitive treatment options may be limited. Unfortunately, many cancers are found too late when outcomes are often deadly. When cancers are diagnosed early, before they have had the chance to spread, the overall 5-year survival rate is four times higher than when diagnosed in later stages.
The MCED Test detects more than 50 types of cancer through a simple blood draw. This test has been shown to detect many cancers that are not commonly screened for today to improve the chances of finding cancer early, allowing the opportunity for earlier treatment. If a cancer signal is found, the results can point to where in the body the cancer is coming from with high accuracy to help you and your healthcare provider guide your next steps. The MCED test looks for genetically related signals present in the blood that may be associated with cancer at the time of the test.
This test is available by prescription only. The test is intended to be used in addition to, and not replace, other cancer screening tests that your healthcare provider recommends.